Therapeutics Company Announces Dissemination of Positive Results From Rhinitis Trial
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute financial advice or an endorsement of any particular investment strategy. The stock market carries inherent risks, and past performance is not indicative of future results.
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). These results were shared via video formats on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology worldwide. This announcement follows the journal's April publication of the peer-reviewed article titled "AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial," which detailed the pivotal trial's findings.
Reach and Impact
Allergy’s social media platforms, which have a reach of over 250,000 readers monthly and more than two million annual downloads of their articles, provide significant visibility for the positive trial results. The study showcased Bentrio's effectiveness compared to the standard saline nasal spray in managing SAR, highlighting critical aspects that could influence both medical practice and patient care in the treatment of seasonal allergies. The NASAR trial enrolled 100 patients during allergy season in Australia, who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Participants self-administered the nasal sprays three times daily for two weeks. The trial achieved its primary efficacy endpoint, demonstrating a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline, with a p-value of 0.013. In addition to meeting its primary endpoint, the study also excelled in secondary efficacy endpoints. These included a statistically significant improvement in health-related quality of life as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), with a p-value of less than 0.001. Furthermore, superior global ratings of efficacy by patients and investigators alike were observed, again with a p-value of less than 0.001. Importantly, Bentrio showed good safety and tolerability similar to that of saline controls, with fewer patients needing relief medication and more experiencing symptom-free days compared to those using saline treatment.
Thomas Meyer, Altamira’s founder, Chairman, and CEO, expressed his excitement about the NASAR trial results being shared through Allergy’s social media channels. He noted, “We are delighted to see the great results from the NASAR trial shared by Allergy, one of the leading medical journals in allergology, with a large audience through its social media channels. The concept of Bentrio as a drug-free and preservative-free spray forming an efficient protective barrier within the nasal cavity appears to resonate well with allergic rhinitis sufferers. We look forward to making the product available in additional countries and helping more patients deal with the daily burden and discomfort associated with allergic rhinitis.”
Bentrio is marketed by Altamira Medica AG, an associate company of Altamira Therapeutics, primarily through distributors. Starting in 2024, Altamira Medica anticipates significant growth in sales, driven by the launch of Bentrio in additional countries. The company expects to conclude partnering discussions and negotiations for distribution in the US, Europe, and other key markets throughout the year.
About Altamira Therapeutics
Altamira Therapeutics is dedicated to developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through its OligoPhore™ and SemaPhore™ platforms. The company’s proprietary delivery technology is used in two flagship siRNA programs: AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, both of which are in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suitable for mRNA and other RNA modalities and is made available to pharmaceutical and biotech companies through out-licensing agreements. While Bentrio's success in the NASAR trial is a significant milestone, Altamira Therapeutics' broader mission encompasses innovative RNA delivery solutions. The company's focus on peptide-based nanoparticle technologies positions it as a pioneer in the realm of RNA therapeutics. These platforms are designed to overcome the challenges associated with delivering RNA molecules to extrahepatic tissues, thereby expanding the potential applications of RNA-based therapies across a multitude of diseases. RNA-based therapies, including siRNA and mRNA treatments, represent a burgeoning field with the potential to address a wide range of medical conditions by targeting genetic and molecular pathways directly. Effective delivery systems are crucial for these therapies to reach their intended sites of action in the body while minimizing off-target effects. Altamira's OligoPhore™ and SemaPhore™ platforms provide a robust solution by facilitating the targeted delivery of RNA molecules to specific tissues beyond the liver.
Altamira’s ongoing research and development efforts aim to enhance the capabilities of their RNA delivery platforms further. The successful application of these platforms in preclinical models for conditions like KRAS-driven cancer and rheumatoid arthritis underscores their potential. As these programs advance toward clinical trials, they hold promise for transforming disease treatment paradigms and improving patient outcomes.
To accelerate the development and commercialization of its RNA delivery technologies, Altamira Therapeutics actively seeks strategic partnerships and collaborations with other pharmaceutical and biotech companies. These alliances are pivotal in leveraging complementary expertise and resources, thereby expediting the translation of cutting-edge research into market-ready therapies. Through out-licensing agreements, Altamira provides access to its delivery platforms, enabling partners to harness these technologies for their therapeutic innovations. Altamira Therapeutics’ dissemination of positive results from the NASAR trial for Bentrio nasal spray via Allergy’s social media channels marks a momentous achievement. The trial’s outcomes not only validate Bentrio’s efficacy and safety but also highlight its potential to improve the quality of life for individuals suffering from seasonal allergic rhinitis. As Altamira continues to expand Bentrio’s market presence and advances its pioneering RNA delivery technologies, the company remains at the forefront of medical innovation.
Investors and stakeholders should monitor Altamira Therapeutics closely as it progresses with its ambitious plans and strategic initiatives. With a strong foundation in RNA delivery and a commitment to addressing unmet medical needs, Altamira is poised to make significant contributions to the healthcare landscape.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute financial advice or an endorsement of any particular investment strategy. The stock market carries inherent risks, and past performance is not indicative of future results. Before making any investment decisions, we strongly recommend consulting with a qualified financial advisor who can tailor advice to your specific circumstances. We do not guarantee the accuracy or completeness of the data presented, and we are not liable for any losses or damages arising from the use of this information. Investing in stocks involves risks, including the potential loss of principal. Always conduct your own research and due diligence before investing in any securities.
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.